Home › Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital
 

Keywords :   


Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital

2016-04-11 07:30:57| Biotech - Topix.net

's stock had its "buy" rating restated by equities research analysts at Roth Capital in a research report issued to clients and investors on Saturday, MarketBeat reports. Other hedge funds have made changes to their positions in the company.

Tags: rating stock capital roth

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.11Spain fines budget airlines including Ryanair 179m
22.11Eastern North Pacific Tropical Weather Outlook
22.11Atlantic Tropical Weather Outlook
22.11Rush PANTS
22.11SBS
22.11/
22.11 YOU
22.11
More »